EyePoint Pharmaceuticals (NASDAQ: EYPT) specializes in creating ocular products for serious eye disorders. The company has developed five FDA-approved sustained-release treatments in ophthalmology. The company’s preclinical development program is focused on drug candidates to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases. The company was formed in 2018 after pSivida announced acquired Icon Bioscience. To…
Novartis shares dip after announcing disappointing Q4 results
Novartis (NYSE:NVS) posted fourth-quarter results today that trailed the consensus forecast. The Basel, Switzerland–based company reported a $2.1 billion net income, an 86% increase in Q4 2019. Earnings per share for the quarter ended Dec. 31 were $1.34 per share on revenue of $12.8 billion. Analysts had anticipated earnings of $1.36 per share. Still, there…